Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2008

01-05-2008 | Clinical-patient Studies

Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients

Authors: Johannes E. A. Wolff, Su Berrak, Susannah E. Koontz Webb, Ming Zhang

Published in: Journal of Neuro-Oncology | Issue 1/2008

Login to get access

Abstract

Even though past studies have suggested efficacy of nitrosourea drugs in patients with high-grade glioma and temozolomide has recently been shown significantly to be beneficial, no conclusive comparisons between these agents have been published. We performed a survival gain analysis of 364 studies describing 24,193 patients with high-grade glioma treated in 504 cohorts, and compared the effects of drugs. The most frequent diagnoses were glioblastoma multiforme (GBM) (72%) and anaplastic astrocytoma (22%). The mean overall survival (mOS) was 14.1 months. The outcome was influenced by several of the known prognostic factors including the histological grade, if the tumors were newly diagnosed or recurrent, the completeness of resection, patients’ age, and gender. This information allowed the calculation of a predicted mOS for each cohort based on their prognostic factors independent of treatment. Survival gain to characterize the influence of treatment was subsequently defined and validated as the difference between the observed and the predicted mOS. In 62 CCNU-treated cohorts and 15 ACNU-treated cohorts the survival gain was 5.3 months and 8.9 months (P < 0.0005), respectively. No detectable survival gain for patients treated with various BCNU-containing regimens was found. Conclusion CCNU- and ACNU- containing regimens were superior to BCNU containing regiments.
Literature
1.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
2.
Hauch H, Sajedi M, Wolff JE (2005) Treatment arms summarizing analysis of 220 high-grade glioma studies. Anticancer Res 25:3585–3590PubMed
3.
Thompson SG, Higgins JP (2002) How should meta-regression analyses be undertaken and interpreted? Stat Med 21:1559–1573PubMedCrossRef
4.
van der Heijden GJ, Donders AR, Stijnen T, Moons KG (2006) Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. J Clin Epidemiol 59:1102–1109PubMedCrossRef
5.
Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474PubMed
6.
Korshunov A, Sycheva R, Golanov A (2005) The prognostic relevance of molecular alterations in glioblastomas for patients age <50 years. Cancer 104:825–832PubMedCrossRef
7.
Stark AM, Nabavi A, Mehdorn HM et al (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63:162–169; discussion 169
8.
Wagner S, Warmuth-Metz M, Emser A et al (2006) Treatment options in childhood pontine gliomas. J Neurooncol 79:281–287PubMedCrossRef
9.
Wrensch M, Rice T, Miike R et al (2006) Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro-oncol 8:12–26PubMedCrossRef
10.
Rubin DB (2004) Multiple imputation for nonresponse in surveys, Wiley-Interscience, June
11.
Grossman SA, O’Neill A, Grunnet M et al (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485–1491PubMedCrossRef
12.
Westphal M, Ram Z, Riddle V et al (2006) Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269–275; discussion 275
13.
Levin VA, Silver P, Hannigan J et al (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18:321–324PubMed
14.
Sweetman S (2006) The complete drug reference. Greenwood Village, Thomson Micromedex
15.
Wakabayashi T, Kajita Y, Mizuno M et al (2001) Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. Neurol Med Chir (Tokyo) 41:115–119; discussion 119–120
16.
Preuss I, Thust R, Kaina B (1996) Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 65:506–512PubMedCrossRef
17.
Laquerriere A, Raguenez-Viotte G, Paraire M et al (1991) Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies. Eur J Cancer 27:630–638PubMedCrossRef
18.
De Vita VTCP, Owens AH Jr, Gold GL, Krant MJ, Edmonson J (1965) Clinical trials with 1,3-Bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25:1876–1881PubMed
19.
Wolff JE, Trilling T, Molenkamp G et al (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125:481–486PubMedCrossRef
Metadata
Title
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients
Authors
Johannes E. A. Wolff
Su Berrak
Susannah E. Koontz Webb
Ming Zhang
Publication date
01-05-2008
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2008
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-008-9533-5

Other articles of this Issue 1/2008

Journal of Neuro-Oncology 1/2008 Go to the issue

Clinical - patient Studies

Meningeal Castleman’s disease with multifocal involvement: a case report and review of literature

clinical -patient studies

Primary choroid plexus papilloma of the sellar region

Clinical -patient studies

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma

lab. Investigation-human/animal tissue

Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas

Clinical-patient studies

Chordoid meningioma: presentation of two case reports, review of the literature, and plea for data standardisation

clinical-patient studies

Longitudinal assessment of childhood optic gliomas: relationship between flicker visual evoked potentials and magnetic resonance imaging findings